Diffuse peritoneal leiomyomatosis is a rare condition where many smooth muscle growths develop across the lining of the abdomen. It most often affects women during the reproductive years, and it can be found during pregnancy or after surgery for fibroids. Early symptoms of diffuse peritoneal leiomyomatosis may be mild, but some people have belly swelling, pelvic pain, pressure, or changes in bowel or bladder habits. Diffuse peritoneal leiomyomatosis often lasts for months or longer, and not everyone will have the same experience. It is usually not cancer and is often not life-threatening, and treatment may include monitoring, hormone-lowering treatment, or surgery depending on symptoms and the size or number of growths.
How many people live with Diffuse peritoneal leiomyomatosis?
Diffuse peritoneal leiomyomatosis appears to be ultra-rare: Orphanet classifies it as affecting fewer than 1 in 1 million people, which suggests fewer than about 8,000 people worldwide (Orphanet, 2024) and fewer than about 340 people in the United States (Orphanet, 2024). These are rough upper-limit estimates, not direct counts, because this condition is known mainly from published individual cases rather than large population tracking studies.
Overview
Diffuse peritoneal leiomyomatosisSymptoms
Diffuse peritoneal leiomyomatosis often causes no symptoms at first. When symptoms do occur, many living with diffuse peritoneal leiomyomatosis notice belly bloating, pelvic or abdominal pain, pressure, or a growing abdominal mass.
Outlook and prognosis
Diffuse peritoneal leiomyomatosis is often slow-growing, and many people do well with monitoring or treatment to control symptoms and reduce pressure on nearby organs. Outlook depends on tumor burden, symptoms, and whether growth returns after surgery or hormone changes.
Causes and risk factors
Diffuse peritoneal leiomyomatosis has no single known cause. Risk rises with high estrogen states such as pregnancy, estrogen therapy, or some birth control. Prior uterine fibroid surgery, especially tissue morcellation, may also increase risk.
Genetic influences
Genetics do not seem to be a major driver of diffuse peritoneal leiomyomatosis in most people, and it is not usually considered an inherited condition. In diffuse peritoneal leiomyomatosis, genetic changes may play a role in some cases, but this is still unclear.
Diagnosis
Diffuse peritoneal leiomyomatosis is usually suspected from imaging, often after unexplained belly swelling, pain, or nodules are found during surgery. Diagnosis is confirmed by examining a tissue sample under a microscope and ruling out cancer.
Treatment and drugs
Diffuse peritoneal leiomyomatosis is often managed with surgery to remove troublesome growths and, in some cases, hormone-lowering medicines because these smooth muscle nodules can respond to estrogen. Care may also include regular imaging follow-up.
Symptoms
Many people living with diffuse peritoneal leiomyomatosis feel well at first, and the condition may only come to light during imaging or surgery for something else. Symptoms vary from person to person and can change over time. When symptoms do happen, they usually come from many smooth muscle growths pressing on nearby tissues inside the abdomen or pelvis, which can lead to discomfort, fullness, or swelling. Some of the early symptoms of diffuse peritoneal leiomyomatosis can look like common digestive or gynecologic problems, so a medical review is often needed.
Many people have no symptoms, especially when the growths are small. Diffuse peritoneal leiomyomatosis is often found by chance during a scan, procedure, or operation done for another reason.
In diffuse peritoneal leiomyomatosis, aching, cramping, or a feeling of pressure in the lower belly or pelvis can happen when the growths irritate tissue or press on nearby organs. Some people also notice a dull lower back ache or discomfort during sex.
The abdomen may feel full, tight, or heavier than usual. Clothes may feel snug, or the belly may look more swollen as the day goes on.
When growths press on the bladder, you may need to urinate more often or feel a stronger sense of urgency. Some people feel low pelvic pressure even when the bladder is not very full.
How people usually first notice Diffuse peritoneal leiomyomatosis?
Diffuse peritoneal leiomyomatosis is often first noticed when someone develops a slowly increasing feeling of abdominal fullness, bloating, pelvic pressure, or pain, sometimes along with a growing waistline or a mass found during an exam or imaging done for another reason. Because these smooth-muscle growths spread across the lining of the abdomen, the first signs of diffuse peritoneal leiomyomatosis can look a lot like more common problems such as fibroids, ovarian cysts, or endometriosis, so many people only learn about it after an ultrasound, CT scan, MRI, or surgery. In some people, there are few or no clear symptoms at first, and the condition is discovered unexpectedly during a C-section, laparoscopy, or another procedure for pelvic or abdominal symptoms.
Types of Diffuse peritoneal leiomyomatosis
Diffuse peritoneal leiomyomatosis is not usually divided into formal, widely accepted subtypes in the way some other conditions are. Symptoms don’t always look the same for everyone. Many living with diffuse peritoneal leiomyomatosis have differences in symptoms based more on where the smooth muscle growths sit in the abdomen, how many there are, and whether they press on nearby organs than on distinct types of diffuse peritoneal leiomyomatosis.
No distinct types
No distinct types of diffuse peritoneal leiomyomatosis are widely recognized. When symptoms differ, it is usually due to the pattern and extent of the growths rather than a separate disease variant.
Can I slow down the onset of symptoms?
Probably not in any proven way: for diffuse peritoneal leiomyomatosis, a rare condition where smooth muscle growths develop in the lining of the belly, there is no good evidence that exercise, diet, sleep, or other lifestyle changes can meaningfully delay when symptoms begin. Research suggests female hormones, especially estrogen, may play a role in some people, so a doctor may review hormone-containing medicines on an individual basis, but that is not the same as preventing the condition, and there are no well-established screening or preventive treatment guidelines. The most helpful step is staying alert to new belly pain, bloating, or a feeling of pressure and getting medical advice early, which may help with earlier care even though it cannot promise a delay in symptoms.
What genetics can tell you about symptoms
For diffuse peritoneal leiomyomatosis, genetics usually cannot predict day-to-day symptoms in a clear or reliable way. Some growths may carry non-inherited genetic changes similar to those seen in uterine fibroids, but these findings are not used to tell which symptoms will appear, how severe they will be, or when they will start. In most cases, symptoms are more closely linked to where the growths are, how many there are, how large they become, and hormone effects than to a known inherited genetic pattern.
Causes and risk factors
Diffuse peritoneal leiomyomatosis often develops in the setting of hormone exposure, not from anything clearly tied to diet, exercise, or other daily habits. Risk is higher during the reproductive years, in pregnancy, and in people who also have uterine fibroids. Prior pelvic surgery, especially fibroid surgery where tissue is broken into small pieces, is one of the best known triggers. Genes may affect how this tissue responds to hormones, but no single inherited cause has been confirmed. It is rarely just one factor, and the main risk factors for diffuse peritoneal leiomyomatosis are hormones, prior surgery, and your underlying biology.
What are the most common causes or risk factors?
Diffuse peritoneal leiomyomatosis is most often linked to hormone-sensitive growth of smooth muscle tissue, so it is seen more often during pregnancy and in people exposed to higher levels of estrogen and progesterone, such as with some hormone treatments. The clearest non-genetic risk factors are having uterine fibroids already and, in some cases, prior fibroid surgery that breaks fibroid tissue into small pieces, which can allow those cells to spread inside the abdomen. A strong inherited cause has not been proven for most people, although a family tendency to develop fibroids may play a role in some cases.
Environmental and biological risk factors
The main risk factors for diffuse peritoneal leiomyomatosis seem to involve hormone exposure and conditions that make smooth muscle tissue more likely to grow. Doctors often group risks into internal (biological) and external (environmental). Because this condition is rare, the exact cause is not always clear, but several patterns show up repeatedly in reported cases.
Diffuse peritoneal leiomyomatosis is seen most often in women during the childbearing years rather than after menopause. This pattern suggests that active female sex hormones are an important biological risk factor.
Pregnancy causes major rises in estrogen and progesterone, which can stimulate smooth muscle growth. Some cases are first noticed during pregnancy or soon after delivery.
Medicines that raise or add estrogen, such as some birth control or menopausal hormone treatments, may increase risk in susceptible people. Doctors often review these exposures when looking for possible triggers.
Many people with diffuse peritoneal leiomyomatosis also have a history of uterine fibroids. This suggests that hormone-sensitive smooth muscle cells may already be more likely to grow.
Genetic risk factors
The genetic causes of diffuse peritoneal leiomyomatosis are still being studied, and no single inherited mutation has been confirmed as the usual cause. Most evidence points to gene changes that arise in the growth itself rather than a condition clearly passed down through families. Science continues to uncover how these elements interact, so doctors usually view inherited risk as uncertain but probably low in most families.
Sporadic pattern: Most diffuse peritoneal leiomyomatosis cases appear to be sporadic, which means they do not usually run strongly in families. Based on current evidence, relatives are not automatically considered high risk just because one family member has this condition.
Acquired changes: Research suggests that many gene changes in diffuse peritoneal leiomyomatosis develop only in the affected tissue after the cells start growing abnormally. These are different from inherited changes that are present from birth in nearly all cells of the body.
Fibroid-like genes: Some tissue studies have found gene changes similar to those seen in uterine fibroids, including changes involving genes such as MED12 or HMGA2. This suggests that diffuse peritoneal leiomyomatosis may share some of the same cell-growth pathways as fibroids.
Chromosome changes: Rare reports have described missing, extra, or rearranged pieces of chromosomes within the growth tissue. These changes may help drive cell growth, but they are not consistent enough to serve as a standard genetic risk marker.
Family history: A clear inherited family pattern has not been established for diffuse peritoneal leiomyomatosis. If several relatives have unusual smooth muscle tumors, a genetics specialist may sometimes look more closely for a broader inherited condition, although this is not typical.
Lifestyle risk factors
Evidence on how lifestyle affects diffuse peritoneal leiomyomatosis is limited, because this is a rare condition and lifestyle is not considered a proven primary cause. Still, habits that raise body fat or estrogen exposure may matter, since many cases appear hormone sensitive. When people ask about lifestyle risk factors for diffuse peritoneal leiomyomatosis, the main concerns are weight-related estrogen production, inactivity, alcohol use, and unmonitored hormone or supplement use.
Higher body fat can increase estrogen production, which may support growth of hormone-sensitive smooth muscle nodules. Gaining weight may also worsen abdominal pressure, bloating, or discomfort if peritoneal masses are already present.
Low activity levels can promote weight gain and metabolic changes that indirectly increase estrogen exposure. Regular movement may help with weight control and improve fatigue, mobility, and abdominal comfort during treatment or monitoring.
A long-term pattern of excess calories and highly processed foods can make weight gain more likely, which may be relevant in an estrogen-responsive condition. A balanced eating pattern that supports a healthy weight may reduce one of the more plausible lifestyle influences on disease activity.
Regular alcohol intake can raise circulating estrogen levels and may also make weight control harder. In someone with diffuse peritoneal leiomyomatosis, that combination could theoretically favor persistence or enlargement of lesions, although direct evidence is sparse.
Risk prevention
Diffuse peritoneal leiomyomatosis is very rare, and there is no proven way to fully prevent it because the exact cause is not well understood. For many living with diffuse peritoneal leiomyomatosis, prevention is mostly about lowering known risks, especially extra exposure to estrogen and spread of fibroid tissue during surgery. Prevention is flexible—it adapts to your life and health background. Regular follow-up also helps catch changes early, especially if new belly swelling, pain, or other early symptoms of diffuse peritoneal leiomyomatosis appear.
Because diffuse peritoneal leiomyomatosis often responds to estrogen, reviewing birth control, fertility drugs, and hormone therapy with your doctor may help lower stimulation of these growths. This does not mean hormones are always unsafe, but they should be chosen carefully based on your history.
If you need fibroid surgery, using techniques that avoid spreading small pieces of tissue inside the abdomen may reduce the chance of diffuse peritoneal leiomyomatosis linked to tissue seeding. This is especially important when minimally invasive surgery is being considered.
Treating uterine fibroids thoughtfully may reduce the need for repeat procedures that can raise risk in some situations. Some prevention is universal, others are tailored to people with specific risks.
Pregnancy can increase hormone levels, so people with a history of diffuse peritoneal leiomyomatosis may need closer monitoring during and after pregnancy. This can help spot growth, pressure symptoms, or complications early.
Can you prevent Diffuse peritoneal leiomyomatosis?
Diffuse peritoneal leiomyomatosis is very rare, and there is no sure way to prevent it because the exact cause is not fully understood. It may be linked to high levels of the hormone estrogen in some people, so a doctor may review whether estrogen-based medicines are really needed, but this has not been proven to prevent the condition.
Transmission
Diffuse peritoneal leiomyomatosis is not an infection, so it cannot be caught from someone else through the air, sex, food, blood, or everyday contact. Many living with Diffuse peritoneal leiomyomatosis wonder how Diffuse peritoneal leiomyomatosis is inherited, but in most cases there is no clear parent-to-child pattern and it is not considered a routinely inherited disorder. It usually develops sporadically, often in connection with hormone-related factors or alongside uterine fibroids, rather than being passed between people. In short, Diffuse peritoneal leiomyomatosis is not infectious, and any genetic contribution appears uncommon and not well defined.
When to test your genes
Genetic testing is not routine for diffuse peritoneal leiomyomatosis itself. It may be worth discussing if you have many fibroids at a young age, a strong family history of fibroids, or relatives with kidney cancer, because this pattern can point to an inherited FH gene condition that may change surveillance and care.
Diagnosis
Diffuse peritoneal leiomyomatosis is usually diagnosed after doctors notice multiple growths in the lining of the abdomen on scans or during surgery, then confirm what those growths are with tissue testing. Because it can look similar to ovarian cancer, spread from another cancer, or uterine fibroids outside the uterus, the diagnosis of diffuse peritoneal leiomyomatosis often takes more than one step. It’s natural to worry when symptoms don’t have a clear explanation.
Doctors ask about symptoms such as belly swelling, pelvic pain, pressure, or a mass that seems to grow over time. They also review prior fibroid surgery, hormone exposure, pregnancy history, and past cancers because these clues can help narrow the cause.
A pelvic and abdominal exam may show fullness, tenderness, or a palpable mass. This exam cannot confirm diffuse peritoneal leiomyomatosis on its own, but it helps guide the next tests.
Ultrasound, CT, or MRI can show multiple smooth muscle-like nodules along the peritoneum, which is the lining of the abdomen. These scans help map where the growths are and whether they look more like benign fibroid-type tissue or something more concerning.
Blood work may be done to check overall health and look for signs that point toward other conditions. Tumor markers and other lab tests may help rule out common conditions, although they do not prove this diagnosis by themselves.
How is Diffuse peritoneal leiomyomatosis diagnosed?
Diffuse peritoneal leiomyomatosis is usually suspected when scans such as ultrasound, CT, or MRI show many growths on the lining of the belly and pelvis, often while checking symptoms like belly swelling, pain, or a mass. Doctors usually confirm it by taking a small tissue sample or removing one of the growths during surgery and looking at it under a microscope, which helps show that the growths are made of smooth muscle and are not cancer. Genetic testing is not usually needed to make the diagnosis, but it may be considered in unusual cases if there is concern about an inherited condition.
Stages of Diffuse peritoneal leiomyomatosis
Diffuse peritoneal leiomyomatosis does not have defined progression stages. This is because it is usually described by where and how much smooth muscle tissue is present in the abdomen, rather than by a predictable step-by-step pattern over time. Doctors usually start with a conversation about symptoms, which can include belly swelling, pelvic pressure, pain, or sometimes no symptoms at all, and the early symptoms of Diffuse peritoneal leiomyomatosis can be easy to mistake for more common gynecologic problems. It is usually diagnosed and monitored with imaging such as ultrasound, CT, or MRI, and confirmation may require surgery or a tissue sample to make sure it is not a different condition.
Outlook and prognosis
The outlook for diffuse peritoneal leiomyomatosis is usually favorable because most cases behave in a benign, slow-growing way and can remain stable or improve, especially when hormonal stimulation is reduced. Prognosis depends on factors such as symptom burden, tumor extent, whether the lesions can be safely removed or observed, and the patient’s hormonal status, including pregnancy or exposure to estrogen-related therapies. Recurrence or persistence can occur, so long-term imaging and clinical follow-up are often recommended even after treatment. Rare cases of malignant transformation to leiomyosarcoma have been reported, which makes careful evaluation of enlarging, atypical, or symptomatic lesions important. Mortality is generally low and deaths directly attributable to diffuse peritoneal leiomyomatosis are uncommon, with risk rising mainly in the unusual setting of malignant change or serious complications from extensive disease.
Long-term effects
For many living with diffuse peritoneal leiomyomatosis, the long-term outlook depends on how many growths are present, where they sit in the abdomen, and whether they keep growing or return after treatment. The long-term picture is often one of a chronic but usually noncancerous condition, with symptoms mainly caused by pressure on nearby organs rather than spread to distant parts of the body. Some people have few ongoing problems, while others deal with repeated symptoms or more than one procedure over time. In rare cases, doctors watch closely for changes that suggest a more aggressive course.
Long-term abdominal or pelvic pain can continue if the growths press on sensitive tissues or come back after treatment. Some may find the discomfort is dull and constant, while others notice flares with movement, periods, or after eating.
Many people with diffuse peritoneal leiomyomatosis have a lasting sense of fullness, bloating, or pressure in the belly. For many, this can mean feeling uncomfortable in fitted clothes or feeling full quickly during meals.
If growths press on the intestines or bladder, long-term effects can include constipation, trouble passing stool, frequent urination, or a constant urge to go. In more severe cases, blockage of the bowel or urinary tract can happen and needs urgent care.
Diffuse peritoneal leiomyomatosis can come back after surgery or continue to grow slowly over time, especially if hormone-sensitive tissue remains. This is one reason the long-term effects of diffuse peritoneal leiomyomatosis may include repeat scans, repeat operations, or ongoing monitoring.
How is it to live with Diffuse peritoneal leiomyomatosis?
Living with diffuse peritoneal leiomyomatosis can feel uncertain because some people have no symptoms at all, while others deal with ongoing belly or pelvic pain, bloating, pressure, or a visibly swollen abdomen that can make movement, exercise, sleep, and sex less comfortable. For many, daily life is shaped not only by symptoms but by repeated scans, doctor visits, and the stress of monitoring a rare condition that is usually benign but can resemble more serious disease on imaging. Family and partners may need to help with appointments, chores, and emotional support, especially during flare-ups or after surgery, but with careful follow-up many people are able to keep working, stay active, and maintain a good quality of life.
Treatment and drugs
Diffuse peritoneal leiomyomatosis is usually treated based on symptoms, the size and number of growths, and whether they are changing over time. If the growths are not causing problems, doctors may suggest regular monitoring with exams and imaging, but if there is pain, pressure, bleeding, or concern about growth, treatment may include surgery to remove larger areas and medicines that lower estrogen levels, since this condition often responds to hormones. Treatment often looks different for each person, and in some cases doctors also review birth control, hormone therapy, or pregnancy plans because these can affect how the condition behaves. Because diffuse peritoneal leiomyomatosis is rare and the best approach depends on age, fertility goals, and test results, care is often guided by a gynecologist or other specialist with follow-up over time.
Can you cure Diffuse peritoneal leiomyomatosis?
There is no single guaranteed cure for diffuse peritoneal leiomyomatosis, but many people can be helped with treatment. Depending on symptoms, the size and number of the growths, and hormone levels, treatment may include careful monitoring, stopping hormone medicines, lowering estrogen, or surgery to remove growths, which can ease symptoms and sometimes make the condition go away.
Non-drug treatment
Living with diffuse peritoneal leiomyomatosis can mean ongoing bloating, pressure, or pain, and for some it is found by chance during imaging or surgery for something else. Because this condition is rare and often behaves differently from one person to another, non-drug care is usually tailored to symptoms, tumor growth, and pregnancy or fertility plans. Managing this condition often involves close follow-up, surgery when needed, and supportive care to help with day-to-day discomfort.
If diffuse peritoneal leiomyomatosis is not causing major symptoms, careful monitoring may be the best first step. This usually includes regular checkups and repeat imaging to watch for growth, new symptoms, or changes that might suggest a different diagnosis.
Surgery may be used when growths cause pain, pressure, bowel or bladder problems, or concern about diagnosis. Depending on the situation, this can involve removing selected nodules or doing more extensive surgery to reduce the amount of tissue.
For people who hope to become pregnant, treatment planning often tries to balance symptom relief with preserving the uterus and ovaries when possible. Family members often play a role in supporting new routines and decisions around timing of surgery, pregnancy, and recovery.
Ongoing ultrasound, CT, or MRI scans can help track how stable the condition is over time. This is especially useful when early symptoms of diffuse peritoneal leiomyomatosis are mild or hard to separate from other abdominal problems.
Your genes may have an impact on how drugs work for you
For many living with diffuse peritoneal leiomyomatosis, treatment often focuses on lowering hormone signals that can help these growths shrink or stop growing, but people do not all respond the same way. Small inherited differences in how the body handles medicines may affect how well a treatment works or how likely side effects are, yet for this condition there is no widely used genetic test that clearly guides which medicine to choose. In real life, this means doctors usually base treatment on symptoms, imaging results, and how someone responds over time, rather than on a gene-based drug test.
Pharmacological treatments
Treatment for Diffuse peritoneal leiomyomatosis often focuses on lowering estrogen, because these growths can shrink when hormone stimulation is reduced. There is no single standard drug plan, and many living with Diffuse peritoneal leiomyomatosis need treatment tailored to age, symptoms, and pregnancy plans. Not everyone responds to the same medication in the same way.
Leuprolide, goserelin, and triptorelin are GnRH agonists that temporarily switch down ovarian hormone production. This can reduce pain, pressure, and the size of hormone-sensitive growths in Diffuse peritoneal leiomyomatosis.
Letrozole and anastrozole lower estrogen made in body fat and other tissues, not just the ovaries. They may be used for medical treatment for Diffuse peritoneal leiomyomatosis, especially when doctors want longer-term hormone suppression or when GnRH drugs are not the best fit.
In some cases, doctors pair hormone-lowering treatment with add-back medicines such as low-dose norethindrone acetate or other hormone replacement to ease hot flashes and bone loss. These drugs do not treat the growths directly, but they can make longer treatment easier to tolerate.
Genetic influences
When diffuse peritoneal leiomyomatosis shows up, many living with it wonder whether it was passed down in the family. Right now, it is not usually linked to one known inherited gene; instead, doctors think hormones and genetic changes that happen within the growths over time may play a bigger role. Family history is one of the strongest clues to a genetic influence, so your doctor may ask whether close relatives have had uterine fibroids or other smooth-muscle growths. Researchers have found that diffuse peritoneal leiomyomatosis can share some of the same genetic changes seen in common fibroids, but these changes are often limited to the tissue itself rather than present in all the body’s cells. That means diffuse peritoneal leiomyomatosis is not usually considered a clearly inherited condition that is predictably passed from parent to child. Because it is so rare, genetic testing is not routine, but it may be considered if your personal or family history suggests a broader inherited tendency to develop tumors.
Is Diffuse peritoneal leiomyomatosis genetic?
Genetics do not seem to be a major driver of diffuse peritoneal leiomyomatosis in most people, and it is not usually considered an inherited condition. In diffuse peritoneal leiomyomatosis, genetic changes may play a role in some cases, but this is still unclear.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a normal part of human biology and are found throughout the general population. Most do not directly affect health and are simply part of normal human diversity. For many genes, having a variant associated with a condition points to a possible link rather than a definite diagnosis, especially when several genes and environmental factors are involved. In some cases, though, one well-understood variant in a specific gene is enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
With diffuse peritoneal leiomyomatosis, treatment often depends on how strongly the growths respond to hormones, because many of these smooth-muscle nodules behave a lot like uterine fibroids. Researchers have found some of the same gene changes seen in fibroids in some cases of diffuse peritoneal leiomyomatosis, which helps explain why hormone-lowering medicines may sometimes shrink the nodules or keep them stable. That is why doctors may consider drugs that lower estrogen levels or reduce hormonal stimulation, especially when surgery would be hard to do or fertility needs to be protected. Genetics is only one factor, and age, pregnancy, past hormone exposure, the size and spread of the nodules, and whether symptoms are getting worse also shape the best treatment for diffuse peritoneal leiomyomatosis. Unlike some cancers, there is no routine pharmacogenetic test that can reliably tell which drug will work best or predict side effects for people living with diffuse peritoneal leiomyomatosis. If genetic testing is done, it is usually used to help confirm the diagnosis and rule out a more aggressive tumor, rather than to choose a specific medicine.
Interactions with other conditions
People living with diffuse peritoneal leiomyomatosis often also have a history of uterine fibroids, and the two can be linked by similar hormone-sensitive smooth muscle growth. Another important aspect is how it may link with other diseases: symptoms of diffuse peritoneal leiomyomatosis can overlap with ovarian cancer, endometriosis, or other causes of abdominal or pelvic masses, so it may take careful testing to tell them apart. For many, this can mean bloating, pressure, or belly pain being mistaken for a different condition at first. Diffuse peritoneal leiomyomatosis may also become more noticeable during pregnancy or with high-estrogen states, which can complicate care if someone is already dealing with other gynecologic problems. In rare cases, doctors monitor closely for changes that could suggest cancer developing within a growth, although this is uncommon. Because these overlaps can affect diagnosis and treatment choices, coordinated care between gynecology, imaging specialists, and sometimes cancer specialists is often helpful.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Diffuse peritoneal leiomyomatosis?
Other conditions that can cause similar belly pain, bloating, pressure, or lumps include uterine fibroids, endometriosis, ovarian growths such as cysts or cancer, and cancer that has spread across the lining of the abdomen. Because diffuse peritoneal leiomyomatosis can look like these conditions on scans or during surgery, doctors often need to rule them out carefully.
History
Many living with diffuse peritoneal leiomyomatosis do not feel ill at first. The condition has often come to light during surgery, imaging, or an evaluation for belly swelling, pressure, or fibroids, when doctors noticed many small growths scattered across the lining of the abdomen and pelvis. Because these growths can look alarming at first glance, early reports often focused on the fear that this might be a widespread cancer.
First described in the medical literature in the 20th century, diffuse peritoneal leiomyomatosis was gradually recognized as a different process from the cancers it could resemble. As more case reports were published, doctors saw a pattern: the growths were usually made of smooth muscle tissue, much like fibroids, and many people affected were in their reproductive years. Early symptoms of diffuse peritoneal leiomyomatosis were often mild, and some may have found out about it only after a scan for another reason or during an operation such as a cesarean birth or fibroid surgery.
Over time, better imaging and, especially, careful tissue testing under the microscope helped specialists separate diffuse peritoneal leiomyomatosis from more dangerous conditions. Researchers also came to suspect that hormones play an important role, since the condition has been reported during pregnancy and in settings where estrogen levels are higher. Later studies added another layer by showing that, in some cases, there may be an underlying genetic cause, although that is not the whole story for everyone.
Today, diffuse peritoneal leiomyomatosis is still considered rare, and much of what doctors know comes from collected case reports rather than large trials. Even so, the history of the condition has made one point much clearer: while it can mimic something severe on scans or at surgery, it is often a separate and more complex diagnosis that needs expert review. That shift in understanding has helped many people avoid unnecessary panic and get care that better fits what is actually going on.